4.01
0.32 (8.67%)
| Previous Close | 3.69 |
| Open | 3.60 |
| Volume | 117,859 |
| Avg. Volume (3M) | 27,009 |
| Market Cap | 3,965,790 |
| Price / Earnings (TTM) | 0.044 |
| Price / Sales | 0.310 |
| Price / Book | 1.78 |
| 52 Weeks Range | |
| Earnings Date | 9 Aug 2023 - 14 Aug 2023 |
| Profit Margin | -73.52% |
| Operating Margin (TTM) | -49.25% |
| Diluted EPS (TTM) | -1.70 |
| Quarterly Revenue Growth (YOY) | 1.30% |
| Current Ratio (MRQ) | 0.550 |
| Return on Assets (TTM) | -61.55% |
AIStockmoo Score
| Value 38% | -5.0 |
| Weak profitability. Thin short-term liquidity. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Return on Capital info | NA |
| Earnings Trend info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 38% | -1.8 |
| No clear trend over the past year. Far below its 52-week high. info | |
| Near its medium-term trend line. info | |
| From our AI technical analysis of the chart. info | NA |
| Technical Setup info | NA |
| Candle Patterns info | NA |
| Sentiment 25% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| Holdings' Sentiment info | NA |
| News Mood info | NA |
| Smart Money | NA |
| Insider Activity info | NA |
| Institutional Flow info | NA |
| Short Interest info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector outperforming the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Price is high against its 52-week average. Down over 5 years. info | |
| No clear trend across the short, medium and long term. info | |
| Levels trending up. info | |
| Final Score | -3.33 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Agile Therapeutics, Inc. | - | - |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| AGRX | 4 M | - | 0.044 | 1.78 | -3.3 |
| SUPN | 6 B | 27.84% | - | 1.59 | -1.0 |
| ANIP | 2 B | - | 13.74 | 2.57 | -0.1 |
| COLL | 783 M | - | 23.13 | 2.72 | 0.1 |
| TKNO | 480 M | - | - | - | 0.8 |
| AQST | 435 M | - | - | - | -1.7 |
Select this tab to load the latest available analysis.
|
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 9.70% |
| % Held by Institutions | 16.02% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |